
Most of the health care sector's headlines are dominated by Big Pharma giants. Legacy companies, including AbbVie (NYSE: ABBV), Eli Lilly (NYSE: LLY), Pfizer (NYSE: PFE), and Merck (NYSE: MRK)—and their lineup of game-changing drugs—receive the lion’s share of attention. But one newcomer is making a splash, and investors looking for growth opportunities in the health space should be paying attention.
Founded in November 2017, Hims & Hers Health (NYSE: HIMS) went public in January 2021. By the end of 2024, the consumer-focused health platform was able to post its first year of profitability, with net income of $126 million.